ARTICLE | Product Development
Amylin is back with Novo’s positive amycretin data
Injectable amycretin shows 24% placebo-adjusted weight loss, giving it the lead in efficacy — at least for now
January 25, 2025 12:07 AM UTC
The first readout from subcutaneous amycretin may allay investor fears about Novo’s long-term positioning in the injectable obesity market, as Phase I/II data from the company’s latest study demonstrated weight loss competitive with Lilly’s retatrutide.
What remains unknown is how the safety profile of the once-weekly amycretin product from Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) compares with competitors, and if there’s any potential for extended dosing beyond once-weekly...